Welcome to CDC stacks | Medication tracker : the 12-dose regimen for latent tuberculosis (TB) infection - 56545 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Medication tracker : the 12-dose regimen for latent tuberculosis (TB) infection
  • Published Date:
    6/21/18
  • Language:
    English
Filetype[PDF-155.65 KB]


  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Patient information : the 12-dose regimen for latent tuberculosis (TB) infection
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatis, STD, and TB Prevention (U.S.)
    Published:
    6/28/18
    Description:
    To treat your latent TB infection, take two medicines (rifapentine and isoniazid) once a week, for 12 weeks. It is important to take all of your medication. If you miss taking your pills for the week, call your doctor/clinic right away. : CS292653A :...
    File Type:
    Filetype[PDF - 150.71 KB]
  2. Treatment of latent tuberculosis infection and tuberculosis disease
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
    Published:
    2016
    Series:
    Self-study modules on tuberculosis ; module 4
    Description:
    In this module, you will learn about the principles of treating latent TB infection (LTBI) and TB disease. A person with LTBI is treated to prevent them from progressing to TB disease. Some people with LTBI are at very high risk of developing TB dise...
    File Type:
    Filetype[PDF - 2.73 MB]
  3. Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data
    Personal Author:
    Stockbridge, Erica L.; Miller, Thaddeus L.; Carlson, Erin K.; Ho, Christine;
    Published:
    May 29 2018
    Source:
    BMC Public Health. 18.
    Description:
    Background : Factors that affect latent tuberculosis infection (LTBI) treatment completion in the US have not been well studied beyond public health settings. This gap was highlighted by recent health insurance-related regulatory changes that are lik...
    File Type:
    Filetype[PDF - 898.76 KB]
  4. Latent tuberculosis infection : a guide for primary health care providers
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.. New Jersey Medical School. Global Tuberculosis Institute..
    Published:
    2013
    Description:
    Developed in partnership with the New Jersey Medical School Global Tuberculosis Institute. : This guide is intended for primary care providers who care for individuals and populations who may be at risk for infection with Mycobacterium tuberculosis. ...
    File Type:
    Filetype[PDF - 524.97 KB]
  5. Treatment of latent tuberculosis infection and tuberculosis disease
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
    Published:
    2008
    Series:
    Self-study modules on tuberculosis ; module 4
    Description:
    The Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-study format. The series consists of a total of nine modules that are separated into two courses. The first course, Modules ...
    File Type:
    Filetype[PDF - 829.72 KB]